Narikazu Boku

机构：Tokyo University of Science, University of Tokyo Hospital, National Cancer Center Hospital East, Tokyo National Hospital, The University of Tokyo · ORCID：0000-0002-1438-707X

发表论文 810 篇 · 总被引 30137 次 · h-index 77

代表论文

Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial (2024 · Gastric Cancer · 被引 42)
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer (2025 · Journal of Clinical Oncology · 被引 15)
A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET). (2025 · Journal of Clinical Oncology · 被引 10)
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial (2025 · Journal of Clinical Oncology · 被引 8)
A phase II study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study) (2025 · International Journal of Clinical Oncology · 被引 6)
Shared decision-making support program for older patients with advanced cancer using a question prompt list and geriatric assessment: A pilot randomized controlled trial (2024 · Journal of Geriatric Oncology · 被引 6)